Seribantumab联合紫杉醇治疗晚期铂耐药或铂难治性卵巢癌的随机II期试验
这项开放标签随机II期研究纳入223例铂耐药或铂难治性卵巢癌患者,按2:1随机接受Seribantumab联合每周紫杉醇或单用紫杉醇。总体意向治疗人群的无进展生存期(PFS)无显著改善(3.75个月 vs 3.68个月,HR 1.027,95%CI 0.741-1.425,P=0.864)。探索性分析提示,肿瘤可检测到HRG mRNA且HER2低表达的患者可能从联合治疗中获益(PFS HR 0.37,95%CI 0.18-0.76,P=0.007)。
要点
- 总体人群中Seribantumab联合紫杉醇未改善PFS(HR 1.027,P=0.864)。
- HRG mRNA可检测且HER2低表达亚组联合治疗PFS HR 0.37(95%CI 0.18-0.76)。
- 作者认为需未来临床试验验证该发现并预选HRG表达和HER2低水平患者。
核心结论
- 在未选择的铂耐药或铂难治性卵巢癌患者中,Seribantumab联合紫杉醇未改善无进展生存期。
- 探索性分析提示,可检测到HRG且HER2低表达这一与药物作用机制直接相关的生物标志物组合,可能识别出从该联合治疗中获益的患者。
- 作者认为需要未来临床试验验证此发现,并应预选HRG表达、聚焦HER2低水平癌症。
研究设计与样本
- 开放标签随机II期研究,评估Seribantumab联合每周紫杉醇对比单用紫杉醇的PFS。
- 纳入铂耐药或铂难治性上皮性卵巢癌、输卵管癌或原发性腹膜癌患者。
- 按2:1随机分配接受Seribantumab联合紫杉醇或单用紫杉醇。
- 患者治疗前接受空心针穿刺活检,并获取存档肿瘤样本用于生物标志物分析。
- 共223例患者随机分配(Seribantumab联合紫杉醇组n=140;单用紫杉醇组n=83)。
主要发现
- 未选择的意向治疗人群中,Seribantumab联合紫杉醇组中位PFS为3.75个月,单用紫杉醇组为3.68个月(HR 1.027;95%CI 0.741-1.425;P=0.864)。
- 在肿瘤可检测到HRG mRNA且HER2低表达的患者中(n=57,占151例有可用生物标志物数据患者的38%),Seribantumab联合紫杉醇组较单用紫杉醇组观察到治疗获益增加(PFS HR 0.37;95%CI 0.18-0.76;P=0.007)。
- 不符合上述标准的患者中HR为1.80(95%CI 1.08-2.98;P=0.023)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking heregulin (HRG) -mediated ErbB3 signaling and inducing ErbB3 receptor downregulation. This open-label randomized phase II study evaluated progression-free survival (PFS) with seribantumab in combination with once-per-week paclitaxel compared with paclitaxel alone in patients with platinum-resistant or -refractory ovarian cancer. A key secondary objective was to determine if any of five prespecified biomarkers predicted benefit from seribantumab. Patients and Methods Patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer were randomly assigned at a ratio of two to one to receive seribantumab plus paclitaxel or paclitaxel alone. Patients underwent pretreatment core needle biopsy; archival tumor samples were also obtained to support biomarker analyses. Results A total of 223 patients were randomly assigned (seribantumab plus paclitaxel, n = 140; paclitaxel alone, n = 83). Median PFS in the unselected intent-to-treat population was 3.75 months with seribantumab plus paclitaxel compared with 3.68 months with paclitaxel alone (hazard ratio [HR], 1.027; 95% CI, 0.741 to 1.425; P = .864). Among patients whose tumors had detectable HRG mRNA and low HER2 (n = 57 [38%] of 151 with available biomarker data), increased treatment benefit was observed in those receiving seribantumab plus paclitaxel compared with paclitaxel alone (PFS HR, 0.37; 95% CI, 0.18 to 0.76; P = .007). The HR in patients not meeting these criteria was 1.80 (95% CI, 1.08 to 2.98; P = .023). Conclusion The addition of seribantumab to paclitaxel did not result in improved PFS in unselected patients. Exploratory analyses suggest that detectable HRG and low HER2, biomarkers that link directly to the mechanism of action of seribantumab, identified patients who might benefit from this combination. Future clinical trials are needed to validate this finding and should preselect for HRG expression and focus on cancers with low HER2 levels.
引用
- Liu JF, Ray-Coquard I, Selle F, et al. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. J Clin Oncol. 2016. PMID: 27998236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。